Advertisement
Australia markets closed

  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     

  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     

  • AUD/USD

    0.6500
    +0.0011 (+0.18%)
     

  • OIL

    82.82
    -0.54 (-0.65%)
     

  • GOLD

    2,328.40
    -13.70 (-0.58%)
     

  • Bitcoin AUD

    98,621.65
    -3,400.97 (-3.33%)
     

  • CMC Crypto 200

    1,382.75
    -41.35 (-2.90%)
     

  • AUD/EUR

    0.6072
    +0.0016 (+0.26%)
     

  • AUD/NZD

    1.0946
    +0.0016 (+0.15%)
     

  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     

  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     

  • DAX

    18,088.70
    -48.95 (-0.27%)
     

  • Hang Seng

    17,201.27
    +372.34 (+2.21%)
     

  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cassava Sciences, Inc. - SAVA

Pomerantz LLP
·2-min read

NEW YORK, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Cassava and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On July 29, 2021, Cassava issued a press release entitled “Cassava Sciences Announces Positive Cognition Data With Simufilam in Alzheimer’s Disease.” Although the press release touted supposedly positive cognition data, analysts and industry observers noted that the data had not demonstrated that Simufilam was more effective at improving cognition than Biogen Inc.’s drug Aduhelm.

ADVERTISEMENT

On this this news, Cassava’s stock price fell $33.82 per share, or 32.72%, to close at $69.53 per share on July 30, 2021.

Then, on August 24, 2021, a citizen’s petition filed with the U.S. Food and Drug Administration (“FDA”) questioned the quality and integrity of study results from Cassava, alleging that some of Cassava’s results appeared to show signs of data manipulation.

On this news, Cassava’s stock price fell another $36.97 per share, or 31.38%, to close at $80.86 per share on August 25, 2021.

Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com
888-476-6529 ext. 7980